Therapeutic	O
Review	B:C0282443
of	O
Methylprednisolone	B:C0309470
Acetate	I:C0309470
Intra-Articular	I:C0309470
Injection	I:C0309470
in	O
the	O
Management	B:C0376636
of	O
Osteoarthritis	B:C0409959
of	I:C0409959
the	I:C0409959
Knee	I:C0409959
-	O
Part	O
1	O
:	O
Clinical	O
Effectiveness	O
.	O

Intra-articular	O
(	O
IA	O
)	O
corticosteroid	O
injections	O
are	O
a	O
common	O
approach	B:C0449445
in	O
the	O
management	B:C0376636
of	O
osteoarthritis	B:C0409959
(	I:C0409959
OA	I:C0409959
)	I:C0409959
of	I:C0409959
the	I:C0409959
knee	I:C0409959
.	O

The	O
effectiveness	O
of	O
injections	B:C1272883
and	O
particular	O
injection	B:C1272883
products	O
is	O
often	O
discussed	O
and	O
debated	O
in	O
clinical	O
arenas	O
.	O

The	O
following	O
therapeutic	O
review	B:C0282443
examines	O
the	O
evidence	O
for	O
intra-articular	B:C0442108
methylprednisolone	B:C0309470
acetate	I:C0309470
(	I:C0309470
MPA	I:C0309470
)	I:C0309470
injections	I:C0309470
in	O
the	O
management	B:C0376636
of	O
OA	B:C0409959
knee	I:C0409959
.	O

A	O
review	B:C0282443
of	O
research	O
evidence	O
,	O
published	B:C0936005
guidelines	I:C0936005
and	O
clinical	O
literature	B:C0023866
was	O
undertaken	O
following	O
an	O
electronic	O
database	O
and	O
relevant	O
literature	B:C0023866
search	O
.	O

The	O
review	B:C0282443
found	O
that	O
there	O
is	O
limited	O
evidence	O
which	O
indicates	O
that	O
a	O
single	O
dose	O
intra-articular	B:C0442108
MPA	B:C0309470
injection	I:C0309470
can	O
provide	O
short	O
to	O
medium	O
term	O
benefits	O
for	O
pain	B:C0030193
,	O
with	O
less	O
evidence	O
for	O
beneficial	O
effects	O
on	O
function	B:C1535551
or	O
stiffness	B:C0162298
.	O

There	O
is	O
heterogeneity	O
across	O
studies	O
and	O
until	O
recently	O
,	O
most	O
studies	O
had	O
only	O
short	O
to	O
medium	O
term	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
periods	I:C1522577
,	O
thus	O
limiting	O
the	O
evidence	O
available	O
on	O
longer	O
term	O
benefit	O
.	O

There	O
was	O
also	O
evidence	O
indicating	O
equivalent	O
overall	O
efficacy	O
of	O
methylprednisolone	B:C0600901
acetate	I:C0600901
to	O
that	O
of	O
other	O
corticosteroid	B:C0443077
products	I:C0443077
.	O

Most	O
guideline	O
recommendations	O
concerning	O
IA	B:C0021488
injections	I:C0021488
for	O
OA	B:C0409959
knee	I:C0409959
have	O
drawn	O
on	O
evidence	O
from	O
pooled	O
data	O
for	O
several	O
corticosteroid	B:C0443077
products	I:C0443077
.	O

The	O
review	B:C0282443
also	O
found	O
there	O
was	O
limited	O
reporting	O
of	O
the	O
incidence	O
of	O
adverse	B:C0877248
events	I:C0877248
in	O
most	O
studies	O
.	O

Overall	O
,	O
methylprednisolone	B:C0600901
acetate	I:C0600901
shows	O
efficacy	O
for	O
symptom	B:C1457887
relief	B:C0451615
in	O
OA	B:C0409959
knee	I:C0409959
.	O

At	O
an	O
individual	B:C0237401
management	B:C0376636
level	O
,	O
evidence	O
for	O
a	O
limited	O
duration	O
of	O
effect	O
needs	O
consideration	O
in	O
injections	B:C1272883
decisions	O
.	O

Furthermore	O
,	O
consensus	O
across	O
clinical	B:C0282451
guidelines	I:C0282451
suggests	O
that	O
the	O
management	B:C0376636
of	O
OA	B:C0409959
knee	I:C0409959
should	O
be	O
individualized	O
to	O
a	O
person	B:C0237401
's	O
clinical	B:C1274016
history	I:C1274016
,	O
degree	O
of	O
disability	B:C0231170
,	O
risk	B:C0035648
factors	I:C0035648
,	O
quality	O
of	O
life	O
and	O
personal	O
preferences	O
,	O
whereby	O
injecting	O
involves	O
a	O
shared	O
decision	O
and	O
forms	O
part	O
of	O
a	O
multimodal	O
approach	O
.	O

